The True Story Behi...
Health Care: Drugs
Celldex Therapeutics Inc. (CLDX: NASDAQ)
$12.30 -0.23 | -1.84%
05/23/13 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| CLDX | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 37.07 | 199.05 | 80.92 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 20.90 | -0.26 | -0.10 |
| Net Income | 0.62 | 0.00 | |
| EPS | -0.45 | 0.00 |
Earnings for CLDX:
| EBITDA | -55.00 |
| REVENUE | 11.20M |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.22 | $-0.25 | $-0.96 | $-1.05 |
| Number of Analysts | 5 | 5 | 6 | 4 |
| High Estimate | $-0.21 | $-0.23 | $-0.92 | $-0.99 |
| Low Estimate | $-0.23 | $-0.28 | $-1.04 | $-1.19 |
| Prior Year | $-0.23 | $-0.25 | $-1.01 | $-0.96 |
| Growth Rate (Year over Year) | 2.61% | 0.00% | 4.95% | -8.85% |
Portfolios with CLDX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- Userbio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Cheap Biotech Stocks Tha...
- User3rdwavemedia Portfolio 1
Latest CLDX Headlines from TheStreet
- 5 Stocks Poised for Breakouts 04.19.13 | 02:04 pm
- Celldex Presents CDX-1127 In Vitro Human Data Consistent With Strong Potency And Safety Profile At AACR 2013 04.08.13 | 01:04 pm
- Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta 03.08.13 | 06:03 am
- Celldex Reports Fourth Quarter And Fiscal 2012 Financial Results 03.07.13 | 08:03 am
- Celldex Therapeutics To Report Fourth Quarter And Fiscal 2012 Financial Results And Host Corporate 2013 Strategic Outlook Call 02.28.13 | 08:02 am
- Positive Data From Celldex's Phase 1 Study Of CDX-301 Support Initiation Of Pilot Study In Hematopoietic Stem Cell Transplantation 02.14.13 | 08:02 am
- Celldex Therapeutics Announces Upcoming Presentation At Leerink Swann Global Healthcare Conference 2013 02.11.13 | 04:02 pm
- Celldex Announces Upcoming Oral Presentation On CDX-301 At The American Society For Blood And Marrow Transplantation 2013 BMT Tandem Meetings 02.11.13 | 09:02 am
- Celldex Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares 02.08.13 | 08:02 am
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
Press Releases for CLDX
- Celldex Therapeutics’ CDX-301 Safely Mobilizes Hematopoietic Cells In Phase 1 Study; Future Development Planned - Business Wire 12.11.12 | 08:12 am
- Final Data From Celldex Therapeutic’s CDX-011 Phase 2 Study In Metastatic Breast Cancer Supports Overall Survival Benefit In Patients With High GPNMB Expression - Business Wire 12.08.12 | 08:12 am
- Celldex Therapeutics Announces Upcoming Presentation At Oppenheimer Healthcare Conference - Business Wire 12.07.12 | 11:12 am
- Celldex Therapeutics Announces Upcoming Data Presentations On CDX-1127 And CDX-011 - Business Wire 12.04.12 | 10:12 am
- Celldex Therapeutics Announces Upcoming Presentation At The Deutsche Bank 2012 DbAccess BioFEST - Business Wire 11.30.12 | 08:11 am
- Celldex Therapeutics Announces Positive Three-Year Survival Data For Rindopepimut Phase 2 Clinical Program - Business Wire 11.15.12 | 05:11 pm
- Celldex Therapeutics Announces Upcoming Presentation At Lazard Capital Markets Healthcare Conference - Business Wire 11.09.12 | 09:11 am
- Celldex Announces Upcoming Data Presentation At The American Society Of Hematology 54th Annual Meeting And Exposition - Business Wire 11.05.12 | 04:11 pm
- Celldex Announces Upcoming Data Presentations At The Society For Neuro-Oncology 17th Annual Scientific Meeting And Education Day - Business Wire 11.05.12 | 07:11 am
- Celldex Reports Third Quarter 2012 Financial Results - Business Wire 11.01.12 | 08:11 am
Partner Headlines for CLDX
- Pre-Market Earnings Report for March 7, 2013 : CNQ, KR, BTE, SFD, NAV, JW/A, FGP, CIEN, EPL, PRIM, CMN, CLDX - NASDAQ 03.06.13 | 09:03 pm
- Anything Can Happen This Year For Celldex - Seeking Alpha 02.18.13 | 09:02 am
- Pre-Market Most Active for Feb 6, 2013 : ELN, QQQ, BAC, BBRY, ZNGA, NOK, GSK, VMED, KB, SNY, ARMH, CLDX - NASDAQ 02.06.13 | 01:02 pm
- Pre-Market Most Active for Dec 11, 2012 : AIG, BAC, HTZ, NOK, FB, HCA, GSK, SIRI, AAPL, URBN, QQQ, CLDX - NASDAQ 12.11.12 | 01:12 pm
- UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex Therapeutics - Benzinga 11.02.12 | 09:11 am
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- Pre-Market Earnings Report for August 10, 2012 : BAM, JCP, HAR, CYD, HSFT, CLDX, HZNP, SCR, XIN, URRE, HSKA, DLGC - NASDAQ 08.09.12 | 08:08 pm
- Even In Clinical Studies, Big Potential For MRI-Guided Procedures - Seeking Alpha 06.28.12 | 09:06 am
- IsoRay: A Potential Small-Cap Bio-Pharma Multi-Bagger - Seeking Alpha 05.29.12 | 09:05 am
- Pre-Market Most Active for May 24, 2012 : BAC, PPL, EMC, NTAP, HPQ, MTGE, CLDX, TS, FB, MT, QQQ, VOD - NASDAQ 05.24.12 | 12:05 pm
